Could adding immunotherapy to chemo shrink cervical tumors better before surgery?
NCT ID NCT07088731
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 29 times
Summary
This study tests whether giving a combination of chemotherapy (nab-paclitaxel and cisplatin) plus an immunotherapy drug (sintilimab) before surgery can improve outcomes for people with locally advanced cervical cancer. The approach is compared to standard chemoradiotherapy. About 180 adults aged 18-70 with specific stages of cervical cancer will take part. The main goal is to see if this pre-surgery treatment helps keep cancer from returning for at least two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Gynecological Oncology
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.